Trial Profile
A Retrospective Study Assessing the Efficacy and Toxicity of Concurrent Nivolumab and Radiotherapy in Patients with Metastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer; Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.